{
    "clinical_study": {
        "@rank": "85627", 
        "brief_summary": {
            "textblock": "Many drug interactions with Warfarin are well documented in the literature, including\n      interactions with a variety of antibiotics. However,in mamy cases it is difficult to predict\n      when the interaction remains theoretical and when it becomes clinically significant and will\n      be reflected in the individual patient. This study's aim is to identify and characterize\n      related conditions (including comorbidities, laboratory test results \u200b\u200band other parameters\n      related to the patient)that might be predictors for drug interactions turning from\n      theoretical to clinically significant."
        }, 
        "brief_title": "Assessment of International Normalized Ratio (INR) Prolongation in Patients Treated Simultaneously With Warfarin and Cephalosporins", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Venous Thrombosis", 
            "Pulmonary Embolism", 
            "Atrial Fibrillation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Embolism", 
                "Pulmonary Embolism", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18 and over\n\n          -  Patients treated with a combination of Warfarin and Cephalosporins\n\n          -  Patients who were hospitalized in the department of internal medicine\n\n          -  Patients who were treated with Warfarin without Cefalosporins\n\n        Exclusion Criteria:\n\n          -  Patients on Warfarin who did not actually receive the drug during their\n             hospitalization\n\n          -  Patients whose medical records were not accessible or didn't contain full data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Warfarin-treated patients who were hospitalized for any reason in the department of\n        internal medicine and were treated with antibiotics from the Cephalosporins group during\n        their hospitalization."
            }
        }, 
        "enrollment": {
            "#text": "236", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857050", 
            "org_study_id": "MMC130210-12CTIL"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Warfarin", 
                "Cephalosporins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "number_of_groups": "1", 
        "official_title": "Assessment of INR Prolongation in Patients Treated Simultaneously With Warfarin and Antibiotics From the Cephalosporins Family,Observational Retrospective Study.", 
        "overall_official": {
            "affiliation": "Meir Hospital, Kfar Saba, Israel", 
            "last_name": "Michael Lishner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Reasons for INR prolongation in patients who were treated with the combination of Warfarin and Cephalosporins", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of thei hospital stay, an expected average of 7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857050"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}